JULIA THIEMI TAKIUTI
Índice h a partir de 2011
8
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina - Médico
4 resultados
Resultados de Busca
Agora exibindo 1 - 4 de 4
- Non-paraneoplastic related retinopathy: clinical challenges and review(2019) TAKIUTI, Julia T.; TAKAHASHI, Vitor K. L.; XU, Christine L.; JAUREGUI, Ruben; TSANG, Stephen H.Autoimmune retinopathy (AIR) is a rare inflammatory condition characterized by progressive visual loss, abnormalities in visual fields and electroretinographic exams, along with presence of circulating anti-retinal antibodies. There are two main forms of AIR: paraneoplastic AIR (pAIR) and presumed non-paraneoplastic AIR (npAIR). NpAIR is considered a diagnosis of exclusion, since it is typically made after other causes of retinopathy have been investigated and the absence of malignancy is confirmed. Work-up of a npAIR case is challenging since there are no standartizaded protocols for diagnosis and treatment. The treatment regimen may vary from case to case, and it can be best guided by a set of parameters including electrophysiological responses, visual outcomes, and presence of anti-retinal antibodies. The purpose of this review is to summarize the principal clinical features, investigation, and management of npAIR.
- Stem cell therapy and regenerative medicine in RPE degenerative disease: advances and challenges(2018) TAKIUTI, Julia T.; TAKAHASHI, Vitor K. L.; APATOFFA, Mary Ben L.; TSANG, Stephen H.Introduction: Retinal degenerative disorders affect patients of all age groups and cause devastating, irreversible vision loss. To date there is no effective treatment capable of restoring retinal function. Pluripotent stem cells, like embryonic stem cells and induced pluripotent stem cells, have the capacity to differentiate into any cell derived from the three germinal layers, including retinal tissue. Considering that, research in transplanted retinal cells derived from pluripotent stem cells has shown progressive results. Areas covered: The article discusses recent relevant clinical trials in retinal pigment epithelium-derived embryonic stem cells and -induced pluripotent stem cells, as well as challenges stem cell research faces from bench to bed side. Expert commentary: Therapies involving stem cells and regenerative medicine have the potential to restore sight and revolutionize the treatment of retinal disease. Clinical trials show promising results. Research surrounding obstacles and challenges is underway.
- Gene therapy in inherited retinal degenerative diseases, a review(2018) TAKAHASHI, Vitor K. L.; TAKIUTI, Julia T.; JAUREGUI, Ruben; TSANG, Stephen H.Hereditary diseases of the retina represent a group of diseases with several heterogeneous mutations that have the common end result of progressive photoreceptor death leading to blindness. Retinal degenerations encompass multifactorial diseases such as age-related macular degeneration, Leber congenital amaurosis, Stargardt disease, and retinitis pigmentosa. Although there is currently no cure for degenerative retinal diseases, ophthalmology has been at the forefront of the development of gene therapy, which offers hope for the treatment of these conditions. This article will explore an overview of the clinical trials of gene supplementation therapy for retinal diseases that are underway or planned for the near future.
- Caring for Hereditary Childhood Retinal Blindness(2018) JAUREGUI, Ruben; CHO, Galaxy Y.; TAKAHASHI, Vitor K. L.; TAKIUTI, Julia T.; BASSUK, Alexander G.; MAHAJAN, Vinit B.; TSANG, Stephen H.Inherited retinal diseases (IRDs) are a major cause of incurable familial blindness in the Western world. In the pediatric population, IRDs are a major contributor to the 19 million children worldwide with visual impairment. Unfortunately, the road to the correct diagnosis is often complicated in the pediatric population, as typical diagnostic tools such as fundus examination, electrodiagnostic studies, and other imaging modalities may be difficult to perform in the pediatric patient. In this review, we describe the most significant IRDs with onset during the pediatric years (ie, before the age of 18). We describe the pathogenesis, clinical presentation, and potential treatment of these diseases. In addition, we advocate the use of a pedigree (family medical history), electro-retinography, and genetic testing as the 3 most crucial tools for the correct diagnosis of IRDs in the pediatric population.